Sellas Life Sciences Group (ehemals Galena Biopharma) (Seite 223)
eröffnet am 30.10.12 22:43:19 von
neuester Beitrag 19.01.24 22:21:17 von
neuester Beitrag 19.01.24 22:21:17 von
Beiträge: 2.935
ID: 1.177.530
ID: 1.177.530
Aufrufe heute: 0
Gesamt: 345.721
Gesamt: 345.721
Aktive User: 0
ISIN: US81642T2096 · WKN: A2PU3T · Symbol: SLS
1,5400
USD
-5,52 %
-0,0900 USD
Letzter Kurs 24.04.24 Nasdaq
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8300 | +161,43 | |
| 9,2900 | +20,96 | |
| 111,75 | +18,87 | |
| 0,6400 | +18,52 | |
| 1,0900 | +14,74 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,2400 | -9,59 | |
| 0,5058 | -12,79 | |
| 9,7200 | -19,60 | |
| 14,510 | -32,32 | |
| 8,0000 | -36,76 |
Beitrag zu dieser Diskussion schreiben
Feedback
Jetzt gehts los,....
wie kann ich den den ADVFN Chart einfügen?
wie kann ich den den ADVFN Chart einfügen?
Antwort auf Beitrag Nr.: 48.842.456 von lunatics am 21.01.15 20:06:02Über den richtigen Einstieg lässt sich streiten.
Der Eigenkapitalwert liegt bei 0,80 $.
Die Aussichten sind aber sehr vielversprechend.
Der Eigenkapitalwert liegt bei 0,80 $.
Die Aussichten sind aber sehr vielversprechend.
Ein candelstick Hammer zumeist ein Zeichen für eine Trendwende im Chart!!
Morgen gehts aufwärts...
Morgen gehts aufwärts...
ahhh,...ich glaub kiry hat sich welche geholt,...Kurs steigt schnell!
Antwort auf Beitrag Nr.: 48.855.005 von kirroyal am 22.01.15 18:46:37DANKE !!
Trading Spotlight
Maxim Group set a $7.00 target price on Galena Biopharma (NASDAQ:GALE) in a report issued on Friday. The firm currently has a a buy rating on the stock.
Galena Biopharma (NASDAQ:GALE) traded up 0.57% during mid-day trading on Friday, hitting $1.76. 1,154,231 shares of the company’s stock traded hands. Galena Biopharma has a 52 week low of $1.43 and a 52 week high of $7.15. The stock’s 50-day moving average is $1.63 and its 200-day moving average is $2.14. The company’s market cap is $213.8 million.
Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.06. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.66 million. The company’s revenue for the quarter was up 38.5% on a year-over-year basis.
A number of other analysts have also recently weighed in on GALE. Analysts at MLV & Co
raised their price target on shares of Galena Biopharma from $3.00 to $5.00 and gave the company a buy rating in a research note on Thursday, November 20th. Analysts at Roth Capital reiterated a positive rating on shares of Galena Biopharma in a research note on Tuesday, November 18th. Finally, analysts at Cantor Fitzgerald reiterated a sell rating and set a $2.00 price target (down previously from $2.25) on shares of Galena Biopharma in a research note on Tuesday, November 4th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $5.83.
Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.
http://tickerreport.com/banking-finance/389424/galena-biopha…
Galena Biopharma (NASDAQ:GALE) traded up 0.57% during mid-day trading on Friday, hitting $1.76. 1,154,231 shares of the company’s stock traded hands. Galena Biopharma has a 52 week low of $1.43 and a 52 week high of $7.15. The stock’s 50-day moving average is $1.63 and its 200-day moving average is $2.14. The company’s market cap is $213.8 million.
Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.06. The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.66 million. The company’s revenue for the quarter was up 38.5% on a year-over-year basis.
A number of other analysts have also recently weighed in on GALE. Analysts at MLV & Co
raised their price target on shares of Galena Biopharma from $3.00 to $5.00 and gave the company a buy rating in a research note on Thursday, November 20th. Analysts at Roth Capital reiterated a positive rating on shares of Galena Biopharma in a research note on Tuesday, November 18th. Finally, analysts at Cantor Fitzgerald reiterated a sell rating and set a $2.00 price target (down previously from $2.25) on shares of Galena Biopharma in a research note on Tuesday, November 4th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company. The company presently has an average rating of Buy and a consensus price target of $5.83.
Galena Biopharma, Inc (NASDAQ:GALE), formerly RXi Pharmaceuticals Corporation, incorporated on April 3, 2006, is a biotechnology company focused on discovering, developing and commercializing therapies addressing unmet medical needs using targeted biotherapeutics.
http://tickerreport.com/banking-finance/389424/galena-biopha…
Kann jemand einen Tageschart einfügen?
Hey,...scheint einen Boden zu geben heute...
Durchsuchen
